Skip to main content
Livermore
Livermore
ZHEN

Redmile Group, LLC

SEC CIK
0001425738
Latest filing
Aug 14, 2026

The latest 13F from Redmile Group, LLC covers Q2 2026 (filed Aug 14, 2026): 39 long positions worth $1.49B. The top 10 holdings make up 73.5% of the portfolio, and the largest is Scholar Rock Holding Corp (SRRK) at 15.9%. Livermore has 22 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
4
Est. +$41.2M
Added
5
Est. +$58.9M
Reduced
23
Est. −$445.6M
Sold out
0

Top 5 holdings

Share of this quarter's portfolio value

  1. SRRKScholar Rock Holding Corp
    15.9%$237.1MHistory
  2. KRYSKrystal Biotech, Inc.
    15.8%$234.9MHistory
  3. STOKStoke Therapeutics, Inc.
    8.7%$129.1MHistory
  4. IMNMImmunome Inc.
    7.0%$104.1MHistory
  5. NRIXNurix Therapeutics, Inc.
    6.6%$98.8MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. AGMBAgomAb Therapeutics NV
    +$33.5MAddedHistory
  2. CLYMClimb Bio, Inc.
    +$16.0MNewHistory
  3. AURAAura Biosciences, Inc.
    +$11.8MNewHistory
  4. STTKShattuck Labs, Inc.
    +$9.39MAddedHistory
  5. ODTXOdyssey Therapeutics, Inc.
    +$7.95MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. AGMBAgomAb Therapeutics NV
    +2.27 pp0.1% → 2.4%History
  2. CLYMClimb Bio, Inc.
    +1.07 pp0.0% → 1.1%History
  3. STTKShattuck Labs, Inc.
    +0.85 pp2.4% → 3.2%History
  4. AURAAura Biosciences, Inc.
    +0.79 pp0.0% → 0.8%History
  5. CLDXCelldex Therapeutics, Inc.
    +0.53 pp0.5% → 1.1%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. SRRKScholar Rock Holding Corp
    −$261.6MReducedHistory
  2. NRIXNurix Therapeutics, Inc.
    −$88.8MReducedHistory
  3. ABSIAbsci Corp
    −$17.5MReducedHistory
  4. KRYSKrystal Biotech, Inc.
    −$15.4MReducedHistory
  5. ANNXAnnexon, Inc.
    −$15.3MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. SRRKScholar Rock Holding Corp
    −13.60 pp29.5% → 15.9%History
  2. ADCTADC Therapeutics SA
    −3.01 pp3.8% → 0.8%History
  3. NRIXNurix Therapeutics, Inc.
    −1.30 pp7.9% → 6.6%History
  4. IMNMImmunome Inc.
    −1.06 pp8.1% → 7.0%History
  5. ANNXAnnexon, Inc.
    −0.79 pp5.3% → 4.6%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$1.49B
−$20.6M (−1.4%) vs. prior quarter
Positions
39
+4 vs. prior quarter
Top 10 concentration
73.5%
Top 10 as share of value
Turnover
6.7%
Q2 2026, one quarter
Average holding period
18.1 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $7.10B (Q1 2021)

Q1 2021: $7.10BQ2 2021: $6.76BQ3 2021: $5.73BQ4 2021: $4.40BQ1 2022: $3.20BQ2 2022: $2.62BQ3 2022: $2.58BQ4 2022: $2.44BQ1 2023: $2.30BQ2 2023: $2.61BQ3 2023: $2.10BQ4 2023: $2.80BQ1 2024: $2.72BQ2 2024: $1.65BQ3 2024: $1.70BQ4 2024: $1.43BQ1 2025: $1.06BQ2 2025: $939.6MQ3 2025: $1.03BQ4 2025: $1.36BQ1 2026: $1.51BQ2 2026: $1.49B
Q1 2021Q2 2026
13F filings of Redmile Group, LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202639$1.49BSRRKKRYSSTOKvs. Q1 2026SEC
Q1 2026May 15, 202635$1.51BSRRKKRYSSTOKvs. Q4 2025SEC
Q4 2025Feb 17, 202634$1.36BSRRKKRYSNRIXvs. Q3 2025SEC
Q3 2025Nov 14, 202540$1.03BSRRKKRYSSTOKvs. Q2 2025SEC
Q2 2025Aug 14, 202548$939.6MSRRKKRYSZYMEvs. Q1 2025SEC
Q1 2025May 15, 202556$1.06BSRRKKRYSFOLDvs. Q4 2024SEC
Q4 2024Feb 14, 202562$1.43BSRRKKRYSNRIXvs. Q3 2024SEC
Q3 2024Nov 14, 202463$1.70BKRYSNRIXFOLDvs. Q2 2024SEC
Q2 2024Aug 14, 202463$1.65BKRYSFOLDNRIXvs. Q1 2024SEC
Q1 2024May 15, 202477$2.72BKRYSFOLDIMNMvs. Q4 2023SEC
Q4 2023Feb 14, 202470$2.80BIMGNKRYSFOLDvs. Q3 2023SEC
Q3 2023Nov 14, 202368$2.10BIMGNKRYSFOLDvs. Q2 2023SEC
Q2 2023Aug 14, 202372$2.61BIMGNKRYSFOLDvs. Q1 2023SEC
Q1 2023May 15, 202376$2.30BFOLDKRYSISEEvs. Q4 2022SEC
Q4 2022Feb 14, 202369$2.44BFOLDKRYSAKROvs. Q3 2022SEC
Q3 2022Nov 14, 202270$2.58BFATEFOLDKRYSvs. Q2 2022SEC
Q2 2022Aug 15, 202271$2.62BFATEFOLDSGENvs. Q1 2022SEC
Q1 2022May 16, 202270$3.20BFATEFOLDARGXvs. Q4 2021SEC
Q4 2021Feb 14, 202271$4.40BFATEFOLDSNCEvs. Q3 2021SEC
Q3 2021Nov 15, 202175$5.73BFATEALLKIGMSvs. Q2 2021SEC
Q2 2021Aug 16, 202186$6.76BFATEIGMSBEAMvs. Q1 2021SEC
Q1 2021May 17, 202186$7.10BFATEALLKIGMS–SEC

13D and 13G filings

Companies where Redmile Group, LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

14 companies, largest stake first.

Companies where Redmile Group, LLC owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
FATEFate Therapeutics Inc13D/A14.90%18.2M shares0.00 ppfrom 14.90%Jan 12, 20217 filingsApr 22, 2026SEC
ANNXAnnexon, Inc.13G/A9.90%17.9M shares0.00 ppfrom 9.90%Feb 16, 20217 filingsJul 8, 2026SEC
RAPTRAPT Therapeutics, Inc.13G/A9.90%13.9M shares–Jun 3, 20224 filingsFeb 14, 2025SEC
ADCTADC Therapeutics SA13G/A9.90%12.7M shares0.00 ppfrom 9.90%Feb 16, 20219 filingsApr 24, 2026SEC
STTKShattuck Labs, Inc.13D/A9.90%10.0M shares0.00 ppfrom 9.90%Dec 26, 20236 filingsJul 17, 2026SEC
RGNXREGENXBIO Inc.13G/A9.90%5.06M shares–Feb 16, 20216 filingsAug 14, 2025SEC
RAPTRAPT Therapeutics, Inc.13G/A9.90%1.77M shares–Aug 14, 20251 filingAug 14, 2025SEC
NGNENeurogene Inc.13G/A9.90%1.57M shares0.00 ppfrom 9.90%Feb 16, 20219 filingsAug 14, 2026SEC
ATRAAtara Biotherapeutics, Inc.13D/A9.90%951.0K shares0.00 ppfrom 9.90%Feb 16, 202110 filingsJul 24, 2026SEC
GRTSGritstone bio, Inc.13G/A8.20%13.2M shares–Feb 16, 20216 filingsFeb 14, 2025SEC
NRIXNurix Therapeutics, Inc.13G/A8.10%8.78M shares−1.80 ppfrom 9.90%Feb 16, 20217 filingsAug 14, 2026SEC
ALXOAlx Oncology Holdings Inc13G/A6.80%9.21M shares−1.70 ppfrom 8.50%Oct 16, 20234 filingsMay 15, 2026SEC
STOKStoke Therapeutics, Inc.13G/A6.70%4.16M shares−1.30 ppfrom 8.00%Feb 16, 20217 filingsMay 15, 2026SEC
AGMBAgomAb Therapeutics NV13G5.60%2.74M sharesNewMay 15, 20261 filingMay 15, 2026SEC

Latest filings

236 filings on file made by Redmile Group, LLC or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Redmile Group, LLC
CompanyFiled (ET)FormStakeChangeEvent dateFiling
NRIXNurix Therapeutics, Inc.Aug 14, 20264:17 PM ET13G/A8.10%8.78M shares−1.80 ppfrom 9.90%Jun 30, 2026SEC
NGNENeurogene Inc.Aug 14, 20264:16 PM ET13G/A9.90%1.57M shares0.00 ppfrom 9.90%Jun 30, 2026SEC
SRRKScholar Rock Holding CorpAug 14, 20264:16 PM ET13G/A3.60%4.31M shares−4.00 ppfrom 7.60%Below 5%Jun 30, 2026SEC
ATRAAtara Biotherapeutics, Inc.Jul 24, 20268:00 PM ET13D/A9.90%951.0K shares0.00 ppfrom 9.90%Jul 22, 2026SEC
STTKShattuck Labs, Inc.Jul 17, 20269:30 PM ET13D/A9.90%10.0M shares0.00 ppfrom 9.90%Jul 15, 2026SEC
ANNXAnnexon, Inc.Jul 8, 20269:30 PM ET13G/A9.90%17.9M shares0.00 ppfrom 9.90%Jul 1, 2026SEC
STTKShattuck Labs, Inc.Jun 11, 20269:00 PM ET13D/A9.90%9.82M shares0.00 ppfrom 9.90%Jun 9, 2026SEC
AGMBAgomAb Therapeutics NVMay 15, 20264:45 PM ET13G5.60%2.74M sharesNewMar 31, 2026SEC
SRRKScholar Rock Holding CorpMay 15, 20264:16 PM ET13G/A7.60%9.07M shares−2.30 ppfrom 9.90%Mar 31, 2026SEC
STOKStoke Therapeutics, Inc.May 15, 20264:16 PM ET13G/A6.70%4.16M shares−1.30 ppfrom 8.00%Mar 31, 2026SEC
IMNMImmunome Inc.May 15, 20264:15 PM ET13G/A4.90%5.56M shares−0.30 ppfrom 5.20%Below 5%Mar 31, 2026SEC
ALXOAlx Oncology Holdings IncMay 15, 20264:15 PM ET13G/A6.80%9.21M shares−1.70 ppfrom 8.50%Mar 31, 2026SEC
ATRAAtara Biotherapeutics, Inc.May 14, 20269:00 PM ET13D/A9.90%951.0K shares0.00 ppfrom 9.90%May 12, 2026SEC
ADCTADC Therapeutics SAApr 24, 20269:31 PM ET13G/A9.90%12.7M shares0.00 ppfrom 9.90%Apr 20, 2026SEC
NRIXNurix Therapeutics, Inc.Apr 24, 20269:28 PM ET13G/A9.90%10.7M shares–Apr 20, 2026SEC
FATEFate Therapeutics IncApr 22, 20269:47 PM ET13D/A14.90%18.2M shares0.00 ppfrom 14.90%Apr 20, 2026SEC
ABSIAbsci CorpApr 14, 20269:00 PM ET13D/A4.90%7.61M shares−0.50 ppfrom 5.40%Below 5%Apr 10, 2026SEC
ADCTADC Therapeutics SAApr 6, 20269:47 PM ET13G/A9.90%12.7M shares−2.80 ppfrom 12.70%Apr 6, 2026SEC
ABSIAbsci CorpMar 26, 20265:00 PM ET13D/A5.40%8.25M shares−1.10 ppfrom 6.50%Mar 24, 2026SEC
NGNENeurogene Inc.Feb 17, 20264:16 PM ET13G/A9.90%1.56M shares0.00 ppfrom 9.90%Dec 31, 2025SEC